

Niina Hanna Talvikki Matikainen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7200742/publications.pdf>

Version: 2024-02-01

56
papers

2,392
citations

236912

25
h-index

214788

47
g-index

59
all docs

59
docs citations

59
times ranked

4283
citing authors

#	ARTICLE	IF	CITATIONS
1	An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans. <i>Cell Metabolism</i> , 2018, 27, 559-571.e5.	16.2	321
2	Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. <i>Diabetologia</i> , 2006, 49, 2049-2057.	6.3	302
3	Postprandial hypertriglyceridemia as a coronary risk factor. <i>Clinica Chimica Acta</i> , 2014, 431, 131-142.	1.1	157
4	Genetic architecture of human plasma lipidome and its link to cardiovascular disease. <i>Nature Communications</i> , 2019, 10, 4329.	12.8	120
5	Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci. <i>Journal of Medical Genetics</i> , 2013, 50, 298-308.	3.2	116
6	PPAR α : an emerging therapeutic target in diabetic microvascular damage. <i>Nature Reviews Endocrinology</i> , 2010, 6, 454-463.	9.6	92
7	Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity. <i>Journal of Internal Medicine</i> , 2017, 282, 187-201.	6.0	89
8	Amerindian-specific regions under positive selection harbour new lipid variants in Latinos. <i>Nature Communications</i> , 2014, 5, 3983.	12.8	81
9	Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 84-94.	4.4	78
10	Postprandial Lipemia Associates with Liver Fat Content. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3052-3059.	3.6	70
11	Paradoxical Dissociation Between Hepatic Fat Content and De Novo Lipogenesis Due to PNPLA3 Sequence Variant. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E821-E825.	3.6	64
12	Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2218-2224.	2.4	58
13	GLP-1 Responses Are Heritable and Blunted in Acquired Obesity With High Liver Fat and Insulin Resistance. <i>Diabetes Care</i> , 2014, 37, 242-251.	8.6	53
14	Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. <i>Atherosclerosis</i> , 2012, 222, 222-228.	0.8	52
15	The Contribution of GWAS Loci in Familial Dyslipidemias. <i>PLoS Genetics</i> , 2016, 12, e1006078.	3.5	48
16	Physiology of Calcium Homeostasis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 575-590.	3.2	42
17	Role of apolipoprotein CIII overproduction in diabetic dyslipidaemia. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1861-1870.	4.4	39
18	Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans. <i>JCI Insight</i> , 2020, 5, .	5.0	38

#	ARTICLE	IF	CITATIONS
19	Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics. <i>Journal of Internal Medicine</i> , 2019, 285, 562-577.	6.0	37
20	Functional imaging with ¹¹ C-metomidate PET for subtype diagnosis in primary aldosteronism. <i>European Journal of Endocrinology</i> , 2020, 183, 539-550.	3.7	36
21	Impaired health-related quality of life in Addison's disease – impact of replacement therapy, comorbidities and socio-economic factors. <i>Clinical Endocrinology</i> , 2014, 81, 511-518.	2.4	33
22	Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat. <i>European Journal of Endocrinology</i> , 2012, 166, 487-492.	3.7	32
23	Hepatic lipogenesis and a marker of hepatic lipid oxidation, predict postprandial responses of triglyceride-rich lipoproteins. <i>Obesity</i> , 2014, 22, 1854-1859.	3.0	31
24	Postprandial lipid and apolipoprotein responses following three consecutive meals associate with liver fat content in type 2 diabetes and the metabolic syndrome. <i>Atherosclerosis</i> , 2010, 211, 308-314.	0.8	28
25	Genetic Variation in SULF2 Is Associated with Postprandial Clearance of Triglyceride-Rich Remnant Particles and Triglyceride Levels in Healthy Subjects. <i>PLoS ONE</i> , 2013, 8, e79473.	2.5	28
26	Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects. <i>Journal of Clinical Lipidology</i> , 2020, 14, 77-87.	1.5	26
27	Coronary Artery Disease Risk and Lipidomic Profiles Are Similar in Hyperlipidemias With Family History and Population-Ascertained Hyperlipidemias. <i>Journal of the American Heart Association</i> , 2019, 8, e012415.	3.7	24
28	The effect of vildagliptin therapy on atherogenic postprandial remnant particles and <sc>LDL</sc> particle size in subjects with Type 2 diabetes. <i>Diabetic Medicine</i> , 2013, 30, 756-757.	2.3	23
29	Interrelationships Between the Kinetics of VLDL Subspecies and HDL Catabolism in Abdominal Obesity: A Multicenter Tracer Kinetic Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4281-4290.	3.6	22
30	Management of Dyslipidemias in the Presence of the Metabolic Syndrome or Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2012, 14, 721-731.	2.9	20
31	Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1191-1201.	4.4	20
32	Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men. <i>PLoS ONE</i> , 2016, 11, e0145890.	2.5	19
33	Adrenal infarction in a healthy pregnant woman. <i>Obstetric Medicine</i> , 2016, 9, 90-92.	1.1	18
34	Fructose intervention for 12 weeks does not impair glycemic control or incretin hormone responses during oral glucose or mixed meal tests in obese men. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 534-542.	2.6	18
35	Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 962-975.	2.4	18
36	The Increase of Apolipoprotein A-V During Postprandial Lipemia Parallels the Response of Triglyceride-Rich Lipoproteins in Type 2 Diabetes: No relationship between apoA-V and postheparin plasma lipolytic activity. <i>Diabetes Care</i> , 2007, 30, 2083-2085.	8.6	17

#	ARTICLE	IF	CITATIONS
37	Health-Related Quality of Life in Patients with Small Intestine Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2018, 107, 366-374.	2.5	16
38	Reviewing statin therapy in diabetes – Towards the best practise. <i>Primary Care Diabetes</i> , 2010, 4, 9-15.	1.8	13
39	Liver Fat and Insulin Sensitivity Define Metabolite Profiles During a Glucose Tolerance Test in Young Adult Twins. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 102, jc.2015-3512.	3.6	12
40	Addison's disease presenting as hyperemesis, hyponatremia and pancytopenia in early pregnancy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2011, 90, 121-122.	2.8	10
41	Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia. <i>BMC Endocrine Disorders</i> , 2014, 14, 90.	2.2	10
42	Circulating makorin ring-finger protein-3 (MKRN3) levels in healthy men and in men with hypogonadotropic hypogonadism. <i>Clinical Endocrinology</i> , 2016, 84, 151-152.	2.4	9
43	Family-specific aggregation of lipid GWAS variants confers the susceptibility to familial hypercholesterolemia in a large Austrian family. <i>Atherosclerosis</i> , 2017, 264, 58-66.	0.8	6
44	Characteristics and outcomes of the Finnish ectopic ACTH syndrome cohort. <i>Endocrine</i> , 2021, 74, 387-395.	2.3	6
45	Postprandial triglyceride-rich lipoproteins in insulin resistance and Type 2 diabetes. <i>Future Lipidology</i> , 2008, 3, 531-543.	0.5	5
46	Aldosterone-to-renin ratio is related to arterial stiffness when the screening criteria of primary aldosteronism are not met. <i>Scientific Reports</i> , 2020, 10, 19804.	3.3	5
47	Effects of <i>PNPLA3</i> I148M on hepatic lipid and very low density lipoprotein metabolism in humans. <i>Journal of Internal Medicine</i> , 2022, 291, 218-223.	6.0	5
48	Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours. <i>Endocrine</i> , 2022, 77, 177-187.	2.3	5
49	ApoA-II HDL Catabolism and Its Relationships With the Kinetics of ApoA-I HDL and of VLDL1, in Abdominal Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1398-1406.	3.6	4
50	Prolonged Hypophosphatemia and Intensive Care After Curative Surgery of Tumor Induced Osteomalacia: A Case Report. <i>Frontiers in Endocrinology</i> , 2021, 12, 686135.	3.5	4
51	Response to Letter on use of functional imaging by ¹¹ C-metomidate PET for primary aldosteronism subtyping. <i>European Journal of Endocrinology</i> , 2021, 184, L11-L12.	3.7	2
52	Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism. <i>European Journal of Endocrinology</i> , 2022, 187, 75-84.	3.7	2
53	Fibroblast Growth Factor 21 is a Regulator of Energy Metabolism in the Liver and Adipose Tissue. , 2014, , 461-472.		1
54	Fibroblast Growth Factor 21 as a Regulator of Energy Metabolism in the Liver and Adipose Tissue. , 2019, , 131-152.		1

#	ARTICLE	IF	CITATIONS
55	Adrenal androgens versus cortisol for primary aldosteronism subtype determination in adrenal venous sampling. <i>Clinical Endocrinology</i> , 2022, 97, 241-249.	2.4	1
56	Do multiparous women need to work or exercise extra hard to control gestational diabetes?. <i>Journal of Sport and Health Science</i> , 2022, , .	6.5	0